Axsome TherapeuticsAXSM +1.83%52 PB Ratio is 227.56 as of Jun. 26, 2026, which is 411% above its 10-year median of 44.54. GuruFocus rates AXSM with a GF Score™ of 52/100 and a GF Value™ of $220.41 (Fairly Valued). The stock has 4 warning signs investors should review. Among 1,232 Biotechnology companies, Axsome Therapeutics ranks worse than 99.68% on this metric.
Axsome Therapeutics Inc stock PB Ratio (=223.47) is close to 5-year high of 240.27.
The historical rank and industry rank for Axsome Therapeutics's PB Ratio or its related term are showing as below:
AXSM'
s PB Ratio Range Over the Past 10 Years
Min: 10.08 Med: 44.54 Max: 240.27
Current: 227.99
During the past 13 years, Axsome Therapeutics's highest PB Ratio was 240.27. The lowest was 10.08. And the median was 44.54.
AXSM's PB Ratio is ranked worse than 99.68% of 1232
companies
in the Biotechnology industry
Industry Median: 2.8
vs AXSM: 227.99
During the past 12 months, Axsome Therapeutics's average Book Value Per Share Growth Rate was -1.80% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -11.70% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 2.30% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 9.80% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Axsome Therapeutics was 137.10% per year. The lowest was -76.60% per year. And the median was 25.70% per year.
Back to Basics: PB Ratio
Axsome Therapeutics (NAS:AXSM) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Axsome Therapeutics PB Ratio Related Terms
Axsome Therapeutics PB Ratio Historical Data
* Premium members only.
The historical data trend for Axsome Therapeutics's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Axsome Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Axsome Therapeutics PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Axsome Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Axsome Therapeutics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Axsome Therapeutics (AXSM) has a PB Ratio of 227.56 as of Jun. 26, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Axsome Therapeutics and its competitors. This is 411% above median its historical median of 44.54. Over the past decade, Axsome Therapeutics' PB Ratio has ranged from 10.08 to 240.27. According to the industry distribution chart, Axsome Therapeutics ranks #1228 out of 1232 companies in the Biotechnology industry, placing it in the top 99.7%.
Is Axsome Therapeutics' PB Ratio too high?
Axsome Therapeutics' current PB Ratio of 227.56 is 411% above median its 10-year median of 44.54. Over the past 10 years, this metric has ranged from a low of 10.08 to a high of 240.27. The Biotechnology industry median PB Ratio is 2.80. Axsome Therapeutics' value of 227.56 is 8027.1% above this industry median. Based on the distribution chart, Axsome Therapeutics ranks #1228 out of 1232 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Axsome Therapeutics has a GF Score™ of 52/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Axsome Therapeutics' PB Ratio compare to IONS and EXEL?
According to the Biotechnology industry distribution chart, Axsome Therapeutics ranks #1228 out of 1232 companies for PB Ratio. This places Axsome Therapeutics in the lower half of its industry. The industry median PB Ratio is 2.80. Axsome Therapeutics' value of 227.56 is 8027.1% above this benchmark. Historically, Axsome Therapeutics' own PB Ratio has ranged from 10.08 to 240.27 over the past decade. While the company's 10-year median is 44.54 vs. the industry median of 2.80, Axsome Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.80, based on 1,232 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Axsome Therapeutics's current PB Ratio of 227.56 is 8027.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Axsome Therapeutics and its competitors. For the Biotechnology industry, the median PB Ratio is 2.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Axsome Therapeutics's current PB Ratio is 227.56, which is 411% above median its own 10-year median of 44.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Axsome Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Axsome Therapeutics (AXSM) is currently considered Fairly Valued. The stock's GF Value™ is $220.41, compared to a current price of $241.67 — trading 9.6% above its estimated fair value. The current PB Ratio is 227.56, which is 411% above median its 10-year median of 44.54 and 8027.1% above the Biotechnology industry median of 2.80. Axsome Therapeutics' overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Axsome Therapeutics (AXSM), the current PB Ratio is 227.56 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Axsome Therapeutics (AXSM) Overvalued in 2026?
Based on GuruFocus' analysis, Axsome Therapeutics stock appears to be overvalued.
The current stock price of $241.67 is trading 9.6% above its estimated GF Value™ of $220.41.
GuruFocus considers Axsome Therapeutics to be Fairly Valued.
Key valuation signals for AXSM:
PB Ratio: 227.56 (411% above median its 10-year median of 44.54)
GF Value™: $220.41 vs. price of $241.67 (9.6% above fair value)
Industry Position: 8027.1% above the Biotechnology median (#1228 of 1232)
No single metric tells the full story. See the AXSM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
52GF Score
Get the complete analysis for AXSM
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AXSM has been successfully added to your 
